Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.41
NYSE:NVS's Cash-to-Debt is ranked lower than
72% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. NYSE:NVS: 0.41 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:NVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 0.95 Max: 3.39
Current: 0.41
0.18
3.39
Equity-to-Asset 0.54
NYSE:NVS's Equity-to-Asset is ranked lower than
64% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NYSE:NVS: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:NVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.58 Max: 0.65
Current: 0.54
0.51
0.65
Debt-to-Equity 0.42
NYSE:NVS's Debt-to-Equity is ranked lower than
57% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. NYSE:NVS: 0.42 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:NVS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12  Med: 0.27 Max: 0.48
Current: 0.42
0.12
0.48
Debt-to-EBITDA 1.71
NYSE:NVS's Debt-to-EBITDA is ranked higher than
54% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. NYSE:NVS: 1.71 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:NVS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.67  Med: 1.27 Max: 1.8
Current: 1.71
0.67
1.8
Interest Coverage 10.72
NYSE:NVS's Interest Coverage is ranked lower than
69% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.08 vs. NYSE:NVS: 10.72 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:NVS' s Interest Coverage Range Over the Past 10 Years
Min: 10.71  Med: 15.82 Max: 30.91
Current: 10.72
10.71
30.91
Piotroski F-Score: 7
Altman Z-Score: 2.55
WACC vs ROIC
6.77%
8.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 17.90
NYSE:NVS's Operating Margin % is ranked higher than
80% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. NYSE:NVS: 17.90 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:NVS' s Operating Margin % Range Over the Past 10 Years
Min: 16.72  Med: 20.76 Max: 22.35
Current: 17.9
16.72
22.35
Net Margin % 26.71
NYSE:NVS's Net Margin % is ranked higher than
92% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. NYSE:NVS: 26.71 )
Ranked among companies with meaningful Net Margin % only.
NYSE:NVS' s Net Margin % Range Over the Past 10 Years
Min: 13.58  Med: 18.23 Max: 35.29
Current: 26.71
13.58
35.29
ROE % 19.16
NYSE:NVS's ROE % is ranked higher than
84% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. NYSE:NVS: 19.16 )
Ranked among companies with meaningful ROE % only.
NYSE:NVS' s ROE % Range Over the Past 10 Years
Min: 8.95  Med: 14.18 Max: 24.29
Current: 19.16
8.95
24.29
ROA % 10.28
NYSE:NVS's ROA % is ranked higher than
81% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. NYSE:NVS: 10.28 )
Ranked among companies with meaningful ROA % only.
NYSE:NVS' s ROA % Range Over the Past 10 Years
Min: 5.19  Med: 8.05 Max: 13.98
Current: 10.28
5.19
13.98
ROC (Joel Greenblatt) % 90.03
NYSE:NVS's ROC (Joel Greenblatt) % is ranked higher than
95% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. NYSE:NVS: 90.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:NVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 53.3  Med: 62.59 Max: 90.03
Current: 90.03
53.3
90.03
3-Year Revenue Growth Rate -0.50
NYSE:NVS's 3-Year Revenue Growth Rate is ranked lower than
72% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NYSE:NVS: -0.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:NVS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.4  Med: 2.3 Max: 12.3
Current: -0.5
-4.4
12.3
3-Year EBITDA Growth Rate -1.80
NYSE:NVS's 3-Year EBITDA Growth Rate is ranked lower than
68% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NYSE:NVS: -1.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:NVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -4.9  Med: 3.4 Max: 15.8
Current: -1.8
-4.9
15.8
3-Year EPS without NRI Growth Rate -8.60
NYSE:NVS's 3-Year EPS without NRI Growth Rate is ranked lower than
73% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. NYSE:NVS: -8.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:NVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 2.9 Max: 82
Current: -8.6
-8.6
82
GuruFocus has detected 3 Warning Signs with Novartis AG NYSE:NVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:NVS's 30-Y Financials

Financials (Next Earnings Date: 2018-10-24)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

NVS Guru Trades in Q3 2017

Pioneer Investments 317,300 sh (+228.81%)
John Rogers 57,697 sh (+16.17%)
Jerome Dodson 321,301 sh (+12.74%)
Ken Fisher 6,632,984 sh (+1.95%)
Tweedy Browne 196,952 sh (+0.27%)
Tom Gayner 3,700 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Steven Cohen Sold Out
Kahn Brothers 26,144 sh (-0.26%)
PRIMECAP Management 21,964,764 sh (-0.59%)
Chris Davis 350,186 sh (-0.75%)
Mario Gabelli 5,395 sh (-1.82%)
Murray Stahl 26,540 sh (-1.85%)
Jim Simons 1,444,200 sh (-2.05%)
Manning & Napier Advisors, Inc 4,392,659 sh (-7.87%)
Dodge & Cox 44,643,925 sh (-10.97%)
Mairs and Power 3,750 sh (-11.76%)
Sarah Ketterer 310,514 sh (-15.85%)
» More
Q4 2017

NVS Guru Trades in Q4 2017

Steven Cohen 65,191 sh (New)
Tom Russo 125 sh (New)
First Eagle Investment 15,848 sh (+23.35%)
Jim Simons 1,716,100 sh (+18.83%)
John Rogers 68,028 sh (+17.91%)
Sarah Ketterer 337,742 sh (+8.77%)
Ken Fisher 6,816,625 sh (+2.77%)
Kahn Brothers 26,610 sh (+1.78%)
Jerome Dodson 321,301 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Mairs and Power 3,750 sh (unchged)
Pioneer Investments Sold Out
Dodge & Cox 44,579,387 sh (-0.14%)
Murray Stahl 26,490 sh (-0.19%)
PRIMECAP Management 21,890,624 sh (-0.34%)
Tweedy Browne 188,746 sh (-4.17%)
Chris Davis 319,186 sh (-8.85%)
Mario Gabelli 2,745 sh (-49.12%)
» More
Q1 2018

NVS Guru Trades in Q1 2018

Pioneer Investments 114,505 sh (New)
Steven Cohen 463,786 sh (+611.43%)
Sarah Ketterer 411,077 sh (+21.71%)
Jim Simons 2,036,698 sh (+18.68%)
Ken Fisher 7,006,474 sh (+2.79%)
John Rogers 69,405 sh (+2.02%)
Jerome Dodson 321,301 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Mario Gabelli 2,745 sh (unchged)
Tom Russo Sold Out
First Eagle Investment Sold Out
PRIMECAP Management 21,818,472 sh (-0.33%)
Murray Stahl 26,366 sh (-0.47%)
Tweedy Browne 187,636 sh (-0.59%)
Dodge & Cox 44,300,162 sh (-0.63%)
Mairs and Power 3,250 sh (-13.33%)
Kahn Brothers 22,010 sh (-17.29%)
Chris Davis 205,456 sh (-35.63%)
» More
Q2 2018

NVS Guru Trades in Q2 2018

Jeremy Grantham 19,500 sh (New)
Eaton Vance Worldwide Health Sciences Fund 295,000 sh (New)
Jim Simons 3,856,288 sh (+89.34%)
Sarah Ketterer 461,962 sh (+12.38%)
Kahn Brothers 23,210 sh (+5.45%)
Ken Fisher 7,325,261 sh (+4.55%)
PRIMECAP Management 22,131,158 sh (+1.43%)
Jerome Dodson 321,301 sh (unchged)
Tom Gayner Sold Out
Mario Gabelli Sold Out
Pioneer Investments Sold Out
Steven Cohen Sold Out
Dodge & Cox 44,131,862 sh (-0.38%)
John Rogers 69,026 sh (-0.55%)
Murray Stahl 26,088 sh (-1.05%)
Tweedy Browne 184,913 sh (-1.45%)
Mairs and Power 3,200 sh (-1.54%)
Chris Davis 170,811 sh (-16.86%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2018-06-30 Reduce -0.38%0.01%$72.44 - $81.87 $ 85.4611%44,131,862
Ken Fisher 2018-06-30 Add 4.55%0.03%$72.44 - $81.87 $ 85.4611%7,325,261
Tweedy Browne 2018-06-30 Reduce -1.45%0.01%$72.44 - $81.87 $ 85.4611%184,913
Chris Davis 2018-06-30 Reduce -16.86%0.01%$72.44 - $81.87 $ 85.4611%170,811
John Rogers 2018-06-30 Reduce -0.55%$72.44 - $81.87 $ 85.4611%69,026
Kahn Brothers 2018-06-30 Add 5.45%0.01%$72.44 - $81.87 $ 85.4611%23,210
Tom Gayner 2018-06-30 Sold Out 0.01%$72.44 - $81.87 $ 85.4611%0
Mario Gabelli 2018-06-30 Sold Out $72.44 - $81.87 $ 85.4611%0
Dodge & Cox 2018-03-31 Reduce -0.63%0.02%$78.56 - $93.91 $ 85.461%44,300,162
Ken Fisher 2018-03-31 Add 2.79%0.02%$78.56 - $93.91 $ 85.461%7,006,474
Chris Davis 2018-03-31 Reduce -35.63%0.04%$78.56 - $93.91 $ 85.461%205,456
Tweedy Browne 2018-03-31 Reduce -0.59%$78.56 - $93.91 $ 85.461%187,636
John Rogers 2018-03-31 Add 2.02%$78.56 - $93.91 $ 85.461%69,405
Kahn Brothers 2018-03-31 Reduce -17.29%0.06%$78.56 - $93.91 $ 85.461%22,010
First Eagle Investment 2018-03-31 Sold Out $78.56 - $93.91 $ 85.461%0
Dodge & Cox 2017-12-31 Reduce -0.14%$80.72 - $86.65 $ 85.462%44,579,387
Ken Fisher 2017-12-31 Add 2.77%0.02%$80.72 - $86.65 $ 85.462%6,816,625
Chris Davis 2017-12-31 Reduce -8.85%0.01%$80.72 - $86.65 $ 85.462%319,186
Tweedy Browne 2017-12-31 Reduce -4.17%0.02%$80.72 - $86.65 $ 85.462%188,746
John Rogers 2017-12-31 Add 17.91%0.01%$80.72 - $86.65 $ 85.462%68,028
Kahn Brothers 2017-12-31 Add 1.78%0.01%$80.72 - $86.65 $ 85.462%26,610
First Eagle Investment 2017-12-31 Add 23.35%$80.72 - $86.65 $ 85.462%15,848
Mario Gabelli 2017-12-31 Reduce -49.12%$80.72 - $86.65 $ 85.462%2,745
Dodge & Cox 2017-09-30 Reduce -10.97%0.39%$81.97 - $86.23 $ 85.461%44,643,925
Ken Fisher 2017-09-30 Add 1.95%0.02%$81.97 - $86.23 $ 85.461%6,632,984
Chris Davis 2017-09-30 Reduce -0.75%$81.97 - $86.23 $ 85.461%350,186
Tweedy Browne 2017-09-30 Add 0.27%$81.97 - $86.23 $ 85.461%196,952
John Rogers 2017-09-30 Add 16.17%0.01%$81.97 - $86.23 $ 85.461%57,697
Kahn Brothers 2017-09-30 Reduce -0.26%$81.97 - $86.23 $ 85.461%26,144
Mario Gabelli 2017-09-30 Reduce -1.82%$81.97 - $86.23 $ 85.461%5,395
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:XSWX:ROG, NYSE:MRK, NYSE:ABBV, NYSE:PFE, XTER:BAYN, LSE:GSK, XPAR:SAN, NYSE:LLY, LSE:AZN, NYSE:BMY, TSE:4503, TSE:4519, TSE:4578, TSE:4568, NYSE:JNJ, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867 » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVSEF.USA,
Headquarter Location:Switzerland
Novartis AG is a part of the healthcare industry. Its main activity is to research and develop healthcare products and pharmaceuticals such as oncology medicines, generic and biosimilar medicines and eye care devices.

Novartis develops and manufactures healthcare products within four main operating segments: branded drugs, generic pharmaceuticals, eye care products, and consumer products. The company sells its products globally with the U.S. representing close to a third of total sales.

Guru Investment Theses on Novartis AG

Jerome Dodson Comments on Novartis - Apr 26, 2017

With the market at all-time highs, it’s difficult to find undervalued stocks with attractive prospects. However, we uncovered a few that we believe are hidden gems. Our first new addition is Novartis (NYSE:NVS), the Swiss pharmaceutical giant. Management is focused on turning around Alcon, its leading eye-care franchise, whose sales have been soft the past few years. We recently met with Mike Ball, the CEO of Alcon, and we’re impressed with his vision to reinvigorate this great business. Meanwhile, investors are giving the company little credit for its enviable portfolio of innovative therapies that should drive revenue growth, including Entresto, an exciting new treatment that provides hope for chronic heart failure patients.

Jerome Dodson (Trades, Portfolio)'s first quarter 2017 Parnassus Funds commentary.

Check out Jerome Dodson latest stock trades

Top Ranked Articles about Novartis AG

Teva’s Recovery Is Just Beginning Despite intense competition, Teva's future does seem bright with a massive corporate restructuring underway, cost cutting and a promising pipeline
Teva Pharmaceuticals (TEVA) is not a company I would typically consider investing in. It was a mere three years ago that it hit an all-time high of $70, only to sink to $11 in November 2017. The decline in stock price correlated with the spike in debt and to many, the glory days of Teva had officially come to an end. Read more...
Invesco European Growth Fund Establishes Position in Criteo in 2nd Quarter Fund adds to several existing positions, including Novartis
The Invesco European Growth Fund (Trades, Portfolio) announced this week that it established a position in Criteo SA (NASDAQ:CRTO) and increased its holdings in nine other companies. Read more...
Top 5 Buys of the Eaton Vance Worldwide Health Sciences Fund Health care-focused fund releases 2nd-quarter portfolio
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed seven new positions when it released its second-quarter portfolio this week. Read more...
Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)
2 Gurus Post Whopper Gains on Struggling Biotech Vanguard and Eaton Vance health care funds profit big as a result of merger with giant Swiss biotech
A pair of health care-oriented funds in the value universe decided to buy up shares of a clinical-stage gene therapy company that drew headlines last year. Now, their investment has triggered estimated gains of up to 97%. Read more...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXS
Novartis to Buy AveXis in $8.7 Billion Deal Company strengthens its lead in the gene therapy space
Expanding its position in the gene therapy and neuroscience space, Swiss pharmaceutical company Novartis AG (NYSE:NVS) announced on Monday it is buying AveXis Inc. (NASDAQ:AVXS) for $8.7 billion in cash. Read more...
Thinking about buying stock in Acadia Pharmaceuticals, Deutsche Bank, General Motors, Novartis, or Spirit Airlines?

Ratios

vs
industry
vs
history
PE Ratio 14.30
NVS's PE Ratio is ranked higher than
82% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.77 vs. NVS: 14.30 )
Ranked among companies with meaningful PE Ratio only.
NVS' s PE Ratio Range Over the Past 10 Years
Min: 5.7  Med: 15.12 Max: 30.99
Current: 14.3
5.7
30.99
Forward PE Ratio 15.17
NVS's Forward PE Ratio is ranked higher than
72% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.60 vs. NVS: 15.17 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 14.30
NVS's PE Ratio without NRI is ranked higher than
83% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.20 vs. NVS: 14.30 )
Ranked among companies with meaningful PE Ratio without NRI only.
NVS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.63  Med: 18.1 Max: 31.15
Current: 14.3
10.63
31.15
Price-to-Owner-Earnings 16.63
NVS's Price-to-Owner-Earnings is ranked higher than
79% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.95 vs. NVS: 16.63 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NVS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.18  Med: 14.4 Max: 40.1
Current: 16.63
7.18
40.1
PB Ratio 2.48
NVS's PB Ratio is ranked higher than
53% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. NVS: 2.48 )
Ranked among companies with meaningful PB Ratio only.
NVS' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 2.42 Max: 3.39
Current: 2.48
1.69
3.39
PS Ratio 3.79
NVS's PS Ratio is ranked lower than
57% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. NVS: 3.79 )
Ranked among companies with meaningful PS Ratio only.
NVS' s PS Ratio Range Over the Past 10 Years
Min: 1.89  Med: 3.31 Max: 5.03
Current: 3.79
1.89
5.03
Price-to-Free-Cash-Flow 19.14
NVS's Price-to-Free-Cash-Flow is ranked higher than
70% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.84 vs. NVS: 19.14 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NVS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.04  Med: 17.35 Max: 26.81
Current: 19.14
7.04
26.81
Price-to-Operating-Cash-Flow 14.82
NVS's Price-to-Operating-Cash-Flow is ranked higher than
71% of the 392 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.00 vs. NVS: 14.82 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NVS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 13.33 Max: 19.39
Current: 14.82
5.75
19.39
EV-to-EBIT 13.24
NVS's EV-to-EBIT is ranked higher than
69% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. NVS: 13.24 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.7  Med: 16.8 Max: 27
Current: 13.24
9.7
27
EV-to-EBITDA 11.21
NVS's EV-to-EBITDA is ranked higher than
70% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. NVS: 11.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.9  Med: 11.8 Max: 19.3
Current: 11.21
7.9
19.3
EV-to-Revenue 4.12
NVS's EV-to-Revenue is ranked lower than
57% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. NVS: 4.12 )
Ranked among companies with meaningful EV-to-Revenue only.
NVS' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 3.6 Max: 5.4
Current: 4.12
2.1
5.4
PEG Ratio 13.00
NVS's PEG Ratio is ranked lower than
91% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. NVS: 13.00 )
Ranked among companies with meaningful PEG Ratio only.
NVS' s PEG Ratio Range Over the Past 10 Years
Min: 1.34  Med: 2.14 Max: 65.62
Current: 13
1.34
65.62
Shiller PE Ratio 18.31
NVS's Shiller PE Ratio is ranked higher than
81% of the 252 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.75 vs. NVS: 18.31 )
Ranked among companies with meaningful Shiller PE Ratio only.
NVS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.73  Med: 15.31 Max: 21.48
Current: 18.31
9.73
21.48
Current Ratio 1.15
NVS's Current Ratio is ranked lower than
82% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. NVS: 1.15 )
Ranked among companies with meaningful Current Ratio only.
NVS' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.29 Max: 2.83
Current: 1.15
0.83
2.83
Quick Ratio 0.89
NVS's Quick Ratio is ranked lower than
79% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. NVS: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.02 Max: 2.48
Current: 0.89
0.59
2.48
Days Inventory 144.83
NVS's Days Inventory is ranked lower than
62% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. NVS: 144.83 )
Ranked among companies with meaningful Days Inventory only.
NVS' s Days Inventory Range Over the Past 10 Years
Min: 117.82  Med: 144.15 Max: 183.45
Current: 144.83
117.82
183.45
Days Sales Outstanding 62.64
NVS's Days Sales Outstanding is ranked higher than
67% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. NVS: 62.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.04 Max: 70.59
Current: 62.64
56.31
70.59
Days Payable 115.58
NVS's Days Payable is ranked higher than
68% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. NVS: 115.58 )
Ranked among companies with meaningful Days Payable only.
NVS' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 115.58
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.48
NVS's Dividend Yield % is ranked higher than
90% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. NVS: 3.48 )
Ranked among companies with meaningful Dividend Yield % only.
NVS' s Dividend Yield % Range Over the Past 10 Years
Min: 2.09  Med: 3.48 Max: 5.11
Current: 3.48
2.09
5.11
Dividend Payout Ratio 0.51
NVS's Dividend Payout Ratio is ranked higher than
88% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. NVS: 0.51 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NVS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.43  Med: 0.65 Max: 0.97
Current: 0.51
0.43
0.97
Forward Dividend Yield % 3.48
NVS's Forward Dividend Yield % is ranked higher than
84% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. NVS: 3.48 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.25
NVS's 5-Year Yield-on-Cost % is ranked higher than
89% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. NVS: 4.25 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.56  Med: 4.25 Max: 6.25
Current: 4.25
2.56
6.25
3-Year Average Share Buyback Ratio 1.10
NVS's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.30 vs. NVS: 1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: 1.1 Max: 2.4
Current: 1.1
-2.1
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 88.10
NVS's Price-to-Tangible-Book is ranked lower than
99% of the 749 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. NVS: 88.10 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.68  Med: 4.67 Max: 12455
Current: 88.1
2.68
12455
Price-to-Intrinsic-Value-Projected-FCF 1.29
NVS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. NVS: 1.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NVS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.69  Med: 1.18 Max: 2.52
Current: 1.29
0.69
2.52
Price-to-Median-PS-Value 1.16
NVS's Price-to-Median-PS-Value is ranked lower than
67% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. NVS: 1.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.14 Max: 3.08
Current: 1.16
0.64
3.08
Price-to-Graham-Number 7.47
NVS's Price-to-Graham-Number is ranked lower than
95% of the 481 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. NVS: 7.47 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NVS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.27  Med: 2.17 Max: 81.67
Current: 7.47
1.27
81.67
Earnings Yield (Greenblatt) % 7.55
NVS's Earnings Yield (Greenblatt) % is ranked higher than
80% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. NVS: 7.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.7  Med: 5.9 Max: 10.3
Current: 7.55
3.7
10.3
Forward Rate of Return (Yacktman) % 2.59
NVS's Forward Rate of Return (Yacktman) % is ranked lower than
66% of the 421 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.96 vs. NVS: 2.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NVS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.2  Med: 12.4 Max: 19.1
Current: 2.59
0.2
19.1

More Statistics

Revenue (TTM) (Mil) $52,237.00
EPS (TTM) $ 5.89
Beta0.91
Volatility18.25%
52-Week Range $72.30 - 94.19
Shares Outstanding (Mil)2,321.80 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 53,429 55,522 59,413
EBIT (Mil $) 12,760 13,690 16,548
EBITDA (Mil $) 17,376 18,276 20,953
EPS ($) 6.18 4.02 4.75
EPS without NRI ($) 6.18 4.02 4.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.14%
Dividends per Share ($) 2.95 3.10 3.37

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}